Canadian Plan B Pharmacy Status Proposal Will Not Address Age Restriction
This article was originally published in The Tan Sheet
Executive Summary
Discussion of an age restriction for purchase of Barr Labs' Plan B (levonorgestrel) will not be included in the Canadian government's evaluation of a potential switch to behind-the-counter status for the emergency contraceptive
You may also be interested in...
CDER’s Galson Cites Application Flaws, Not Politics, In Plan B Decision
Barr Labs submitted a marketing plan for behind-the-counter sale of Plan B (levonorgestrel .75 mg), but FDA was "unable" to review the package
ECs in Canada
Women's Capital Corp.'s progestin-only morning-after pill, Plan B, could be available "behind-the-counter" in Canada within a year, group says. WCC submitted an application to Health Canada March 6 to switch the EC from prescription-only to nonprescription status; if approved, Plan B would be dispensed by trained pharmacists operating under a protocol developed by the Canadian Pharmacists Association and Society of Obstetricians & Gynecologists of Canada. Application includes results from a label comprehension study of 600 American women, as well as post-marketing safety data from Europe. WCC also is in final stages of an actual-use study involving 600 women in Washington; once it is complete, the group will have enough information to submit an application to FDA, which it plans for late summer...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC